Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: EC:3.4.21.4 (trypsin)
 42,187 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Carrageenan or thrombin-induced aggregation of plasma-free rabbit platelets was inhibited by calcium and magnesium chelating agents, by N-ethylmaleimide and by drugs that increase the intra-cellular cyclic AMP content. Inhibitors of prostaglandin (PG) synthetase were only partially active, and had to be present in the platelet suspension to inhibit aggregation. Inhibition of PG synthetase, as evaluated by bioassay and by AA-induced platelet aggregation, was not reduced when inhibitors were washed from platelets. The phospholipase A2 inhibitors bromophenacyl bromide and mepacrine, the chymotrypsin inhibitor tosylphenylalaninechloromethylketone, catalase and dithiothreitol also inhibited aggregation, whereas inhibitors of trypsin failed to do so. Incubation of rabbit platelet-rich plasma with carrageenan was followed by generation of PG-like and of rabbit aorta contracting activities. Generation of these activities was inhibited by drugs effective against aggregation, and also by non-steroidal anti-inflammatory drugs. Aggregation of rabbit platelets by carrageenan and by thrombin does not appear to be dependent upon activation of PG synthetase, although PG-like substances are formed during aggregation.
 ...
PMID:Involvement of mediators in the interaction of platelets and carrageenan. 41 34

Thrombin-mediated platelet aggregation and release is enhanced by the presence of C3, C5, C6, C7, C8, and C9 of human complement. The interaction of thrombin with its receptor on the platelet membrane initiates activation of complement on the platelet surface. Trypsin-mediated platelet function is not enhanced by the addition of complement, probably because trypsin has no receptor on the platelet surface so activation of complement is triggered in the fluid phase and not on the platelet surface. Activation of complement by thrombin led to production of dimers of the C5b-9 complex on the platelet surface. These complexes were eluted from the platelet membrane and were identified physicochemically and morphologically. The mechanism of complement-induced enhancement of platelet function is not clear, however, it probably is mediated via the arachidonic acid transormation pathway because this activity was blocked by known inhibitors of cyclo-oxygenase, namely, aspirin and indomethacin.
 ...
PMID:Human complement in thrombin-mediated platelet function: uptake of the C5b-9 complex. 47 64

Endothelial cells in culture can modulate platelet aggregation and vascular tone, in part by producing prostacyclin (PGI2), a powerful vasodilator and inhibitor of platelet aggregation, but also by their ecto-ADPase activity, which initiates the conversion of pro-aggregating ADP to adenosine, a potent vasodilator and platelet inhibitor. We have now demonstrated that cultured aortic endothelial cells exposed to trypsin, thrombin or other stimuli can liberate a high proportion of their adenine nucleotides without substantial loss of lactate dehydrogenase. ADP rapidly accumulates extracellularly, reaching biologically active concentrations before there is further breakdown to adenosine. Whether this selective release of nucleotides is a response to damage, or whether it represents a specific secretory mechanism remains to be resolved. Cultured aortic smooth muscle cells can secrete adenine nucleotides in a similar manner, but extracellular conversion to adenosine occurs much faster.
 ...
PMID:Vascular endothelial and smooth muscle cells in culture selectively release adenine nucleotides. 48 3

Thrombin first activates and then inactivates factor VIII and for this reason thrombin has been considered responsible for the inactivation of factor VIII which occurs during clotting. Experiments described in this paper indicated that the activity of factor VIII is not reduced in factor IX or factor X deficient sera, while on the other hand this factor becomes inactivated in blood anticoagulated with high concentrations of hirudin which inhibit thrombin activity completely. This suggests that some other factor, besides thrombin, which is generated only in trace amounts in factor IX or factor X deficient plasmas, is also able to inactivate factor VIII. Purified factor X activated with insolubilized trypsin was added to purified preparations of factor VIII, which were free of both fibrinogen and prothrombin. Factor X a was allowed to act for 5-60 minutes and then inactivated with phenylmethanesulfonyl fluoride. Depending on the duration of the action of factor X a partial or complete inactivation of factor VIII was observed. This inactivation was also observed in the presence of hirudin, thus excluding the possibility that the effect was due to contamination with trace amounts of thrombin.
 ...
PMID:Inactivation of factor VIII by a mechanism independent of the generation of thrombin. 50 1

When 125I-thrombin was incubated with foreskin fibroblasts, cervical carcinoma cells or fibrosarcoma cells of human origin, or with secondary chick embryo cells or Chinese hamster lung cells, it became directly linked to its cell surface receptors. The thrombin-receptor complex (TH-R) was derived exclusively from a pool of 125I-thrombin that had become specifically bound to the cell surface. The linkage was probably covalent, since the complex was resistant to boiling in sodium dodecyl sulfate and 2-mercaptoethanol. Raising the pH to 12 disrupted TH-R, but did not affect a similar complex between epidermal growth factor and its receptor, suggesting that the linkage of these mitogens to their receptors was different. Mild trypsin treatment removed the ability of cells to form TH-R; however, after a 24-h incubation in serum-free medium, trypsin-treated cells recovered the capacity to form TH-R, suggesting that TH-R resulted from interaction of 125I-thrombin with a cellular rather than a serum component. The mitogenic response of cells to thrombin was inversely related to the fraction of specifically bound 125I-thrombin represented by TH-R. The role of TH-R in mitogenesis may be clarified in future studies by obtaining clones of Chinese hamster lung cells that vary in their capacities to form TH-R and to respond to the mitogenic action of thrombin.
 ...
PMID:Direct linkage of thrombin to its cell surface receptors in different cell types. 54 38

By using ammonium sulfate, Arg-Sepharose and gel filtration, an urinary trypsin inhibitor (UTI) with molecular weight of 67,000 (UTI7) was isolated from normal human urine. The yield of UTI7 was about 3,200 U per liter of urine. When urine was acidified, an uropepsin-like substance was activated which caused molecular weight change of UTI7. New UTIs had molecular weight of 45,000 and 22,000 (UTI4-5 and UTI-2-2), respectively. These inhibitors showed a strong effect on trypsin, alpha--chymotrypsin and lesser extent on plasmin and elastase, but had no effect on esterolytic activity on thrombin and the first components of complement Cls an Clr.
 ...
PMID:[Trypsin inhibitors in human urine (author's transl)]. 55 61

Derivatives of benzamidine inhibit competitively the activity of the serine proteinases trypsin, plasmin, thrombin, and of the clotting factor Xa. The inhibitor activities (Ki-values) of various benzamidine derivatives against the several enzymes were compared. Besides parallels, deviations in the corresponding structure-activity relationships were found. From these results it is concluded that the similar enzymes exhibit certain differences in the structure of the primary and secondary binding sites.
 ...
PMID:Inhibition of serine proteinases by benzamidine derivatives. 61 39

The syntheses are described of p-guanidino-L-phenylalanine and some of its derivatives. alpha-N-(p-Toluenesulphonyl)-p-guanidino-L-phenylalanine methyl ester is an excellent substrate of bovine trypsin (EC 3.4.21.4) (Km 57 micron; kcat. 320s-1 at pH 7.4-8.0) and a very poor substrate of human thrombin (EC 3.4.21.5) (Km 190 micron, kcat. 0.2s-1) and bovine chymotrypsin (EC 3.4.21.1). The ester inhibits thrombin clotting activity. It also inhibits the amidase and esterase activities of human thrombin, this inhibition being of the mixed type. The inhibition constant, K1, of the order of 1 micron, increases with increasing inhibitor concentration. This suggests that the enzyme binds the inhibitor at multiple sites. The importance of the residue at the P1 position [notation of Berger & Schechter (1970) Philos. Trans. R. Soc. London Ser. B 257, 249-264] in determining the selectivity of a substrate or quasi-substrate among trypsin-like enzymes is borne out. p-Guanidino-L-phenylalanine may have a use in the synthesis of selective peptide inhibitors of thrombin.
 ...
PMID:The interaction of alpha-N-(p-toluenesulphonyl)-p-guanidino-L-phenylalanine methyl ester with thrombin and trypsin. 62 42

18-25-fold purified alpha-thrombin, having high esterase activity and coagulating ability of 2500 NIH u per 1 mg of protein, was isolated using chromatography of commercial thrombin through SP-Sephadex C-50. Limited proteolysis of alpha-thrombin on the column with immobilized trypsin resulted in the appearance of beta-thrombin with alpha-thrombin-like esterase activity and tracing coagulating activity (2-5 NIH u per 1 mg of protein). Molecular weight analysis of alpha- and beta-thrombin forms suggests that a peptide (or peptides) with Mr of 1100 is splitted off under proteolysis. Some similarity is revealed in kinetic parameters (Km(app) and kkat) of TAME and BAME hydrolysis by alpha- and beta-thrombin, although Km(app) is somewhat low (approximately 2-fold) for alpha-thrombin. Investigation of TAME hydrolysis kinetics by both thrombin forms at a wide range of substrate concentrations has revealed the effect of substrate activation. Kinetic constants Ks and beta for high substrate concentrations are calculated. It is suggested that the similarity of alpha- and beta-thrombin action on arginine esters and sharp differences in their effect on fibrinogen may be a result of a disturbance of substrate-binding region of beta-thrombin active site.
 ...
PMID:[Comparison of the catalytic properties of alpha- and beta-forms of thrombin]. 65 98

The N(alpha)-arylsulfonyl-L-arginine ethyl- and propyl esters were synthesized and the kinetics of their hydrolysis by thrombin was studied. The values of kcat and Km were shown to depend on the structure of the leaving group and to decrease in the line: OCH3 greater than OC2H5 greater than OC3H7. Using methanol as an additional nucleophile, the kinetic parameters - k2, k3 and Ks - were measured for both thrombin- and trypsin-catalysed reactions. A similarity of two enzymes at the stage of Michaelis complex formation was revealed: the Ks values for both enzymes were practically identical (18.10(-5)M). The differences between thrombin and trypsin were observed at the stages of chemical conversion of substrates and were especially well-pronounced at the stage of acylation. It was shown that the k2 values for thrombin were lower than that for trypsin and the k2/k3 ratio of TAME hydrolysis by trypsin was equal to 21, while that for thrombin was 4.5. This finding is indicative of an essential role of the acylation step in thrombin-catalysed hydrolysis of the esters under study.
 ...
PMID:[Determination of the kinetic parameters of individual stages of M(alpha)-arylsulfonyl-L-arginine ester hydrolysis by thrombin and trypsin]. 65 99


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>